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Serum and urine samples were collected from 33 NCC patients before the albendazole treatment, 3–6 and 12 months PT. At 3
months PT, 24 (72.7%) patients had no detectable CT/MRI lesions and 9 (27.2%) patients had persistent lesions. Antibody response
to crude soluble extract (CSE), excretory secretory (ES), and lower molecular mass (LMM) (10–30KDa) antigenic fraction of T.
solium cysticerci was detected in serum and urine samples by ELISA. Before the treatment, out of 33 NCC children, 14 (42.4%), 22
(66.6%), and 11 (33.3%) serum samples were found positive with the use of CSE, ES, and LMM antigen, respectively. At 3–6 months
PT, positivity rate was 5 (15.1%), 2 (6%), and 4 (12.1%) and at 12 months PT, positivity rate was 5 (15.1%), 0, and 3 (9%) with the use
of CSE, ES, and LMM antigen, respectively. There was no significant difference in the positivity with the use of three antigens in
pretreatment and PT urine samples. The study suggests that the use of ES antigen to detect antibody in serum samples may serve
better purpose to evaluate the therapeutic response in patients with NCC.
1. Introduction
Neurocysticercosis (NCC) is caused by the presence of
Taenia solium larvae, the cysticerci in central nervous system,
and is the most common cause of epilepsy in India. It is
estimated thatT. solium cysticercosis affects 50million people
worldwide [1]. Conservative estimates describe 50,000 deaths
every year due to neurocysticercosis [2]. It is regarded as
a major public health threat and economic burden in the
developing countries of Asia, Africa, and Latin America.
Important foci exist in USSR, India, China, Pakistan, Philip-
pines, and Indonesia [3, 4]. Highest prevalence rates exist in
communities where there is close contact between man and
pigs, hygienic standards are low, and pork is eaten raw or
undercooked. In a survey over a period of 20 years in north
India, it was found in 5.9% of 103 epileptics and 11.1% amongst
patients attending a neurology clinic in Postgraduate Institute
of Medical Education and Research, Sawhney et al. [5].
The disease was earlier thought to occur less frequently in
children and most of the available literature on NCC is
concerned with adult patients [6]. Now the disease is being
increasingly recognized in children [7]. Up to 50%of children
with partial seizures in the Postgraduate Institute of Medical
Education and Research (PGIMER) emergency service of
the Nehru hospital, Chandigarh, India, have a recognizable
underlying cause, the most common being neurocysticerco-
sis and tuberculoma, both of which are amenable to specific
pharmacotherapy [8].
Therapeutic measures for NCC can be considered as
symptomatic treatment and definitive medical or surgical
treatment. In the definitive therapy, for cyst destruction,
antihelminthic drug albendazole has been used in a dose of
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15mg/kg/day in two or three divided doses for 28 days and
shorter durations of 14 days to 8 days have also been used
[9]. In a placebo-controlled trial of 1 week versus 4 weeks of
albendazole therapy in children with one to three enhancing
lesions, both regimens were found to be equally effective [10].
Resolution of lesion on CT scans at 3 months was seen in
68.3% and 68.8% in the 1-week and 4-week treatment groups,
respectively. Seizure control at 1 year was similar in both
groups. Although resolving of the active lesions on computer
tomography was observed after 3 months of the treatment,
cured patients remain seropositive even after one year of the
treatment [11]. It indicates that persistent seropositivity does
not necessarily indicate active infection. Although studies to
evaluate the assessment of therapeutic response by detecting
humoral immune response [12–14] and detection of antigens
[15–18] in ELISA are available, serological methods to assess
the therapeutic response in correlation with the radioimag-
ing methods are scanty. Recently, HP10 antigen detection
enzyme-linked immunosorbent assay was compared with
the magnetic resonance imaging (MRI) in NCC follow-
up patients [19]. Moreover, nonavailability of radioimaging
facilities in many centers of endemic countries indicates
the need to develop a serological method to evaluate the
therapeutic response in NCC patients. Excretory secretory
(ES) antigens are a complex mixture of proteins since they
are metabolic products of live metacestodes; thus antibodies
against ES can be considered as an indication of the presence
of live parasite [20, 21]. The ES antigens have been found
to be a better serodiagnostic antigen than crude antigen in
other parasitic diseases [22–25]. In our earlier studies, we
reported that the ES antigens are highly sensitive in both
ELISA and EITB assay for the detection of antibody in serum
samples for the diagnosis of neurocysticercosis in children
[26–28]. The aim of the present study was to evaluate the
efficacy of excretory secretory antigens in comparison to
crude and lowermolecular mass antigenic fractions in ELISA
to assess the therapeutic response to albendazole in children
with neurocysticercosis.
2. Materials and Methods
2.1. Patients and Controls. A cohort study was carried out in
a tertiary hospital setting at the Advanced Pediatrics Centre
(APC), the Department of Pediatric Medicine attached to the
Postgraduate Institute of Medical Education and Research,
Chandigarh, India. In total, 36 clinically suspected and
radiologically proven NCC children and 5 children who
attended outpatient department with minor illness (control)
were enrolled in this study after taking due consent from
the parents or guardians. Children with enhancing lesions in
brain MRI are called active lesion NCC cases. The samples
collected from 5 control children were used to assess the cut-
off ELISA absorbance (OD) values. Serum and urine samples
were collected from NCC children and controls.
Follow-up: children with NCC were given albendazole
orally in a dose of 15mg/kg/day for 28 days in case of multiple
lesions or 8 days in case of single lesion patients. All the
NCC patients were followed for one year and two follow-up
samples were collected; one between 3 and 6 months and
second sample at 12 months after the treatment. Patients were
examined again clinically (for symptoms) and radiologically
(for persistence of the lesion) at 3 months after ending the
treatment. CT/MRI of the NCC patients was available only
3 months after completion of the treatment and was not
done 12 months following treatment. Radiological evaluation
of the pre- and posttreatment NCC children was done by
the radiologists in the Department of Radiodiagnosis and
Imaging, Postgraduate Institute of Medical Education and
Research, Chandigarh, India.The radiologists were not aware
of the ELISA results. Patients with the sustained enhancing
lesions are considered as nonresponsive and patients with
calcified lesions are considered as responders.
2.2. Preparation of the Antigens. Cysts were obtained from
naturally infected pork from the local slaughter house,
Chandigarh, India, and confirmed microscopically as T.
solium cysticerci.
2.2.1. Crude Soluble Extract (CSE Antigen). Crude soluble
antigen was prepared from the cysts isolated as detailed out
earlier [28, 29]. Briefly, cysts were washed for 4 hours in
phosphate buffer saline (PBS) (pH 7.4) containing antibiotics
and antifungal agents. Cysts were suspended in normal saline
and homogenized at 4∘C in a tissue grinder to form a
pulp. The pulp was sonicated and centrifuged and the clear
supernatant obtained was stored at −20∘C in 1mL aliquots till
further use.
2.2.2. Excretory-Secretory Antigen. T. solium cysticerci sepa-
rated from pork muscle were subjected to in vitro cultivation
as detailedout earlier [28, 30]. Briefly, intact larvae with
smooth translucent bladder wall and containing fluid were
washed extensively for 2-3 hours in PBS and distributed
into tissue culture flasks containing the RPMI 1640 medium
followed by incubation at 37∘C in 5% CO
2
. The medium
was discarded after 12 and 24 hrs and replenished each time
with fresh medium. Cell-free medium was collected every
24 hrs thereafter for 1 week.Themembrane components were
removed from the collected medium by centrifugation at
10,000 rpm for 30min and the antigen was concentrated by
precipitation in the 90% saturated solution of ammonium
sulfate. The precipitate was dissolved in PBS and subjected to
extensive dialysis against PBS (pH 7.2), overnight at 4∘C and
stored at −20∘C for further use.
2.2.3. Lower Molecular Mass Antigen Fraction (10–30 KDA).
The LMM antigen fraction was essentially prepared using
electroelution as detailed out earlier [28]. Briefly, CSE antigen
of Taenia solium cysticerci was fractionated by SDS-PAGE
using 4% stacking gel and 15% separating gel under reducing
conditions. By comparing the standard protein molecular
weight marker, the gel corresponding to 10–30 kDa portions
was cut and the antigen was eluted from the gel by using
electroeluter. The antigen was further purified by dialysis,
overnight at 4∘C against PBS.
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All the three antigens were estimated for the protein
concentration just before use [31].
2.3. ELISA. The ELISA was carried out according to the
standard method with slight modifications [28]. The opti-
mum dilutions of the antigens, serum, and conjugate were
determined by checker board titration. In the final set-up
of ELISA, by using the results of checker board titration, all
the serum samples were used at 1 : 400, 1 : 800, and 1 : 1600
dilutions and urine samples as undiluted. The optimum
concentrations of the antigens were found to be 2𝜇g, 1 𝜇g,
and 0.002 𝜇g per well and conjugate dilutions, 1 : 40,000,
1 : 40,000, and 1 : 30,000 for both serum and urine with the
use of CSE, ES, and LMM antigens, respectively. Each well
of the 96-well microtiter plate (Nunc Inter Med, Denmark)
was coated with 100 𝜇L optimum dilutions of the antigen in
carbonate bicarbonate buffer and incubated at 4∘C overnight
followed by washing 3 times with PBS containing 0.02%
Tween-20 (PBST). The nonspecific sites were blocked with
2%BSA in PBST and plate was incubated at 37∘C for 1 hr
followed bywashing for 3xwith PBST.Three dilutions (1 : 400,
1 : 800, and 1 : 1600) of the test, positive and negative control
sera prepared in 1%BSA inPBST, andneat urine sampleswere
added (100 𝜇L) to each well.Three positive, 5 negative control
sera and urine samples, and one blank were included in each
plate. These plates were incubated at 37∘C for 1 hr and again
washed 3x with PBST followed by addition of 100𝜇L/well
of optimum dilution of anti-human IgG conjugated with
horse radish peroxidase (Sigma Aldrich) in 1%BSA in PBST
and incubated at 37∘C for 1 hr. Following incubation, plates
were washed 3x with PBST and ortho-phenylenediamine and
H
2
O
2
were subsequently added as substrate (100 𝜇L/well).
The plates were incubated in darkness for 15–30min and the
reaction was stopped by adding 3M H
2
SO
4
. The absorbance
of the contents of each well was read at 492 nm in an A4
ELISA reader (Eurogenetics, Tessenderlo, Belgium).
The cut-off absorbance value (OD) in each plate for serum
and neat urine was determined by the mean absorbance of
the 5 negative control sera/urine samples plus 2 S.D. The test
sera/urine giving absorbance that was equal to and/or above
the cut-off OD was considered to be ELISA positive at that
dilution. Each sample was tested in duplicate.
2.4. Statistical Analysis. Positivity rate was calculated at the
cut-off dilution (1 : 400) of the sera (to get 95% confidence
interval) and neat urine samples. Significance in the dif-
ference of ELISA positivity in the samples collected before
and after treatment was analyzed by using the McNemar
Test Exact. A 𝑃 value of <0.05 was taken as indicative of a
statistically significant difference.
3. Results
3.1. Demographic and Radiological Characteristics of
NCC Cases
3.1.1. Pretreatment Evaluation. The age of the enrolled chil-
dren in this study was between 3 and 12 years. Brain scans
Table 1: Number of serum samples positive before the treatment,
at 3–6 and 12 months following the treatment with the use of ∗CSE,
∗∗ES, and ∗∗∗LMM antigens.
Antigen 𝑛 = 33 (%)
Before Rx 3–6 months 12 months
∗CSE 14a (42.4) 5b (15.1) 5c (15.1)
∗∗ES 22d (66.6) 2e (6) 0f
∗∗∗LMM 11g (33.3) 4h (12.1) 3i (9)
𝑃 values a versus b; d versus e; g versus h; e versus f<0.05; b versus c; h versus
i >0.05 (McNemar Test Exact).
∗CSE: crude soluble extract; ∗∗ES: excretory secretory; ∗∗∗LMM: lower
molecular mass; 𝑛 = number studied.
of 36 NCC children by CT/MRI, revealed single cysticercus
granuloma (SCG) in 31 (86.1%) andmultiple lesion neurocys-
ticercosis (MLNCC) in 5 (13.9%) patients. Out of 31 patients
with SCG, 29 (93.5%) had active (enhancing lesion) and 2
(6.5%) had calcified lesion and, out of 5 MLNCC cases, 4
(80%) had active and 1 (20%) had calcified lesions. The 3
children with calcified lesions were excluded from this study
(2 children with SCG + 1 patient with MLNCC). All of the
33 (100%) NCC children presented with seizures and of these
focal seizures (88.9%) were more common compared to gen-
eralized seizures (11.1%). The second most common clinical
presentation was headache (44.8%) followed by nausea and
vomiting (38.4%).
3.1.2. Posttreatment (PT) Evaluation (Radiological versus Clin-
ical). To assess response to the treatment, CT was repeated 3
months after completion of therapy. Out of 29 SCG patients,
the PT analysis showed that single active cyst persisted in 7
(24.1%) patients. Out of 4 MLNCC patients, multiple active
cysts persisted in 2 (50%) patients. Twenty-four (72.7%)
patients had no CT/MRI detectable lesion at 3 months PT.
Thus, on the basis of repeat CT/MRI evaluation, 24 (72.7%)
cases were categorized as responders and 9 (27.2%) with
persistent lesion as nonresponders.
Out of 24 responders, 1 (4.1%) patient had persistent
symptoms (headache) and, out of 9 nonresponders, two
patients (22.2%) (one with headache and one with seizures
and vomiting) had persistent symptoms even 12 months after
the treatment.
3.2. Antibody Detection
3.2.1. Serumbefore Treatment. Antibody response toCSE, ES,
and LMM antigenic fraction was positive in 14 (42.4%), 22
(66.6%), and 11 (33.3%) serum samples, respectively (Table 1
and Figures 1 and 2). Antibody response to ES antigen is
significantly higher than CSE and LMM antigenic fractions.
It is indicating that the sensitivity of ES antigen is significantly
higher than CSE and LMM antigens to detect antibody in
children with NCC.
3.2.2. Serum after Treatment. After 3–6 months PT, antibody
response to CSE, ES, and LMM antigenic fraction was
positive in 5 (15.1%), 2 (6%), and 4 (12.1%) serum samples, and
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Figure 1: (a) Scattergram of absorbancemeasured by ELISA to detect serum antibody against CSE antigen in childrenwith neurocysticercosis
before and after the treatment: from 33 clinically suspected and radiologically proven NCC children, serum samples were collected before
and after 3–6 months and 12 months completion of the treatment with albendazole. Antibody response against CSE was measured by using
ELISA. Solid line indicates cut-off OD value. (b) Scattergram of absorbance measured by ELISA to detect serum antibody against ES antigen
in children with neurocysticercosis before and after the treatment: from 33 clinically suspected and radiologically proven NCC children,
serum samples were collected before and after 3–6 months and 12 months completion of the treatment with albendazole. Antibody response
against ES was measured by using ELISA. Solid line indicates cut-off OD value. (c) Scattergram of absorbance measured by ELISA to detect
serum antibody against LMM antigen in children with neurocysticercosis before and after the treatment: from 33 clinically suspected and
radiologically proven NCC children, serum samples were collected before and after 3–6 months and 12 months completion of the treatment
with albendazole. Antibody response against LMM was measured by using ELISA. Solid line indicates cut-off OD value.
12months following the treatment, it was positive in 5 (15.1%),
0, and 3 (9%) patients, respectively (Table 1 and Figures 1
and 2). Statistical significance in serum antibody response to
different antigenic fractions was compared in Table 1.
3.2.3. Urine before Treatment. Antibody response to CSE, ES,
and LMM antigenic fraction was positive in 20 (60.6%), 18
(54.5%), and 16 (48.4%) urine samples, respectively (Table 2).
Statistical significance in urine antibody response to different
antigenic fractions was compared in Table 2.
3.2.4. Urine after Treatment. 3–6 months PT, antibody
response to CSE, ES, and LMM antigenic fraction was
positive in 17 (51.5%), 12 (36.3%), and 16 (48.4%) samples,
Table 2: Number of urine samples positive before the treatment and
at 3–6 and 12 months after treatment with the use of CSE, ES, and
LMM antigens in ELISA (%).
Antigen NCC = 33 (%)
Before Rx After 3–6 months After 12 months
CSE 20a (60.6) 17b (51.5) 16c (48.4)
ES 18d (54.5) 12e (36.3) 11f (33.3)
LMM 16g (48.4) 16h (48.4) 15i (45.4)
𝑃 values a versus b and c; d versus e and f; g versus h and i = >0.05; d versus
f = <0.05
and 12 months following the treatment, it was positive
in 16 (48.4%), 11 (33.3%), and 15 (45.4%) urine samples,
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Figure 2: ELISA percent seropositivity in (a)NCC children before the treatment with albendazole, 3–6months and 12months after treatment.
(b) NCC treatment nonresponders at 3–6months and 12months after treatment. (c) NCC treatment responders at 3–6months and 12months
after treatment.
respectively (Table 2). No significant difference in antibody
positivity was found with the use of CSE and LMM antigens
in the urine samples collected 3–6 months and 12 months
PT in both responders and nonresponders, while significant
difference was found with the use of ES antigen before the
treatment, 3–6 months and 12 months PT (Table 2).
3.3. CT/MRI versus ELISA Positivity after Treatment. Out of
24 patients with resolving lesions onCT/MRI scans, 4 (16.6%)
and 3 (12.5%) serum samples were positive at 3–6 months
PT; 4 (16.6%) and 2 (8.3%) serum samples were persistently
positive even 12 months PT with the use of CSE and LMM
antigens, respectively. Out of 9 patients with persistent lesions
in CT/MRI, one sample (11%) was positive at 3–6months and
12months PT, with the use of CSE/LMMantigens, while, with
the use of ES antigen, only one sample was reactive after 3–
6 months both in responder and in nonresponder groups,
but none of the serum samples were reactive 12 months PT
(Table 3).
4. Discussion
In the present study, the efficacy of three types of antigens
(CSE, ES, and LMM) was assessed by ELISA to detect the
posttreatment IgG antibody response in serum and urine
sample collected from 33 NCC children following treatment
with albendazole. ELISA is a simple and economical test,
which compliments CT/MRI scans in the immunodiagnosis
of NCC. Many studies have reported the PT (albenda-
zole/praziquantel) radiological evolution of the lesions by
indicating the decrease in number and size, total resolution
or gliosis, and calcification [10, 32, 33]. In the present study,
PT analysis of CT/MRI reports in 33 cases showed persistence
of lesions in 27.2% (single cyst in 7 patients andmultiple active
6 BioMed Research International
Table 3: Posttreatment radiological reports versus antibody response before the treatment, 3–6 months and 12 months following the
treatment.
Radiological findings
𝑛 = 33
Serum antibody response
Number positive (%)
CSE ES LMM
3–6mth 12mth 3–6mth 12mth 3–6mth 12mth
Resolved lesion (𝑛 = 24) 4 (16.6) 4 (16.6) 1 (4.1) N.D 3 (12.5) 2 (8.3)
Persistent lesion (𝑛 = 9) 1 (11) 1 (11) 1 (11) N.D 1 (11) 1 (11)
N.D: not in detectable levels; mth: month; 𝑛: number studied.
cysts in 2 cases) of NCC cases at 3 months PT. This is in
agreement with the previous report conducted in the same
institute where disappearance of the lesion was reported in
75.7% of children 6 months PT with albendazole [32].
Very few reports indicate the evaluation of ELISA to
detect humoral immune response in the assessment of
therapeutic response after the treatment with the use of
crude [12], purified, and heterologous antigens [13]. In the
present study, with the use of crude antigen, out of 14 serum
samples positive before the treatment, 5 (35.7%) samples were
persistently seropositive even 3–6 months and 12 months
PT. In our earlier study, evaluation of antibody responses
to CSE antigen in PT serum samples was attempted in 10
NCC patients who reported 1, 3, and 6 months following
albendazole treatment (15mg/kg body weight for 15 days). In
that study, out of 6 seropositive cases, 6 (100%), 6 (100%), and
3 (50%) serum samples were found to be persistently positive
for IgG response to CSE antigen after 1, 3, and 6 months PT,
respectively [12].
To the best of our knowledge, reports of use of ES
antigen for the assessment of humoral antibody response
in NCC patients after treatment are lacking. In the present
study, with the use of ES antigen, out of 22 serum samples
positive before the treatment, 2 (9%) (one responder and one
nonresponder) serum samples were positive at 3–6 months
PT, and none of the serum samples was reactive at 12
months PT. The reason for absence of antibody in serum 12
months following treatment may be due to the absence of the
excretory secretory products from the inactive or calcified
lesions, thereby indicating the seronegative response to the
ES antigens in the serum samples [21]. The study suggests
that the detection of antibody response in serum samples
to ES antigens than CSE or purified antigenic fractions
may be useful for the evaluation of therapeutic response in
neurocysticercosis patients and positivity with the use of ES
antigens may indicate the persistence of the active lesions in
the brain.
In the present study, out of 11 serum samples positive
before the treatment, with the use of 10–30 kDa antigenic
fractions, 4 (36.3%) serum samples at 3–6 months PT and 3
(27.2%) samples at 12 months PT were persistently positive.
In our earlier study, with the use of Sephadex G-200 purified
antigenic fraction (PAF-II) of C. cellulosae in ELISA, the
antibody response was found to be persistently positive in 4
(36.4%) out of 11 serum samples collected within 3–6 months
of albendazole treatment [34]. In another study, in ELISA
with the use of antigen B, out of 6 seropositive cases, 5
(83.3%), 3 (50%), and 1 (16.7%) serum samples had detectable
IgG at 1, 3, and 6 months following treatment, respectively
[12]. The results of the present study are in agreement
with the recent study using the Cysticercus fasciolaris larval
stage of T. taeniaeformis antigen. In that study, among the
responders, 86.7% (IgG) and 79.5% (IgM) had converted to
negative antibody titers at 6 months PT. Thirteen (81.2%) of
16 and 12 (80%) of 15 nonresponders continued to show high
anti-cysticercus IgG and IgM titers, respectively. The study
suggested that a negative ELISA result for both IgG and IgM
antibodies denotes the cure of NCC [13]. In the present study,
before the treatment, all of the serum samples positive with
the CSE and LMM antigens were also positive with the use
of ES antigens. In the case after treatment, the serum samples
positive with the LMM antigens were also positive in ELISA
with the CSE antigen.
In the present study, with the use of urine samples, there
was no significant difference in the ELISA positivity with
the use of crude/ES/10–30 kDa antigenic fractions for the
detection of antibody at 3–6 months and 12 months PT. It
indicates that the urine sample may not serve useful purpose
for evaluation of therapeutic response in the neurocysticer-
cosis patients. However, until now, no reports are available
regarding evaluation of urine samples to assess the antibody
response following treatment.
In the present study, although no significant correlation
was found between the radiological findings at 3 months
PT and antibody response at 3–6 months PT, there was
significant correlation between the clinical outcome of the
patient and the antibody response. Out of 9 patients with
persistent lesions, none of them were seropositive at 12
months PT in ES ELISA.This supports the earlier reports that
persistence of lesions solely in the brain does not necessarily
constitute active infection [11]. In an earlier study from
Mexico, direct relationship between the living stage of cysts
and the presence of antibodies against E/S antigens has been
reported [21].
In conclusion, the present study suggests that the pres-
ence of detectable antibody in serum against the excretory
secretory antigens irrespective of their CT/MRI observation
may indicate the active infection and also indicate the
necessity to continue the treatment. The limitation of the
present study was that CT/MRI of the NCC patients was
available only 3 months after completion of the treatment.
CT/MRI was not done 12 months following treatment and so
BioMed Research International 7
correlation of the antibody response with the radioimaging
reports 12 months after treatment was not possible.
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